The global breast cancer therapeutics market was valued at $17.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $35.5 Billion.
As per WHO, 508 000 women worldwide died due to breast cancer in 2011 (Global Health Estimates, WHO 2013) and the trend keep rising. Although it is considered a disease of the developed world, almost 50% of breast cancer cases and 58% of deaths occur in less developed countries (GLOBOCAN 2008). Due to recent development in therapeutic and radiation therapy, survival rates ranging from 80% or over in North America, Sweden, and Japan to around 60% in middle-income countries and below 40% in low-income countries
Long exposure to endogenous estrogens, such as early menarche, late menopause, late age at first childbirth is among the most important risk factors for breast cancer. Exogenous hormones, oral contraceptive, and hormone replacement therapy put patients at higher risk for breast cancer. Breastfeeding has a protective effect.
“Optimal Price Point (OPP) for Breast Cancer Therapeutic Products”
Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the breast cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.
Breast Cancer Therapeutics Market by “Treatment Categories”
We have segmented the breast cancer treatment market into chemotherapy, surgery & radiation therapy, targeted therapy, and hormonal therapy. Chemotherapy category can be further segmented into antimetabolites, anthracyclines, epothilones, taxanes and alkylating agents. Hormone therapy into aromatase inhibitors and Selective Estrogen-Receptor Modulators (SERMs). Targeted therapy into monoclonal antibodies and tyrosine kinase inhibitors. During our study, we have observed the dominance of chemotherapy followed by surgery & radiation therapy. Targeted therapy is the fastest growing segment due to superior benefits such as targeted action, minimum damage to surrounding tissue, quick recovery rate, increased efficacy, and less toxic levels.
Breast Cancer Therapeutics Market by “Drug Class”
Note- Breast Cancer Therapeutic Market by “Drug Class” doesn’t include Chemotherapy, Surgery and Radiation Therapy.
The global breast cancer drug market was valued at $12.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $24.2 Billion.
We have broadly segmented the market as HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, Hormone Receptor. We have listed leading drugs within those categories in our report. The highest-growing segment in this category is HER2-positive with sales rising from $7.6 billion to $18.5 billion during the forecasting period growing at a CAGR of 8.2%. However, some segments are relatively small in size and growing at a CAGR of 4.8%.
Breast Cancer Therapeutics Market by “Distribution Channel”
We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking requirement to the outcome.
North America accounted for the maximum revenue share of over 40% in 2017 due to increased patient number, lifestyle followed by women, late pregnancy, usage of contraceptives, availability of treatment options, better reimbursement plan, and RND. Followed by EU- Top 5 countries contribute $4.6 Billion in 2017 and expected to reach $6.5 Billion by 2023.
In last 40 years, Breast Cancer treatment market dominated by two drugs – tamoxifen for hormone-positive breast cancer and Roche’s Herceptin (trastuzumab) for the HER2-positive subtype. Herceptin dominance will end soon by launch of biosimilars and new-generation agents.
With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.
“Competitive Landscape” and “Merger & Acquisition Insights”
The key market participants include Novartis International AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Eisai Co. Ltd., GlaxoSmithKline plc, Pfizer Inc., Puma Biotechnology Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Some of the most notable transactions in the recent past include,
- Bayer paying Loxo Oncology $400 million upfront in November 2017 for global rights to larotrectinib and LOXO-195, a second-generation TRK-fusion drug.
- Roche Holding acquiring Ignyta in a $1.7 billion all-cash deal, exploring origin agnostic approaches to cancer treatment.
Breast Cancer Therapeutics Market by Treatment Categories (Revenue, Million, 2014 – 2025)
- Surgery & Radiation therapy
- Targeted Therapy
- Hormonal Therapy
Breast Cancer Therapeutics Market by Drug Class (Revenue, Million, 2014 – 2025)
- HER2 Inhibitors
- Herceptin (Trastuzumab)
- Tykerb (Lapatinib)
- Kadcyla (Ado-trastuzumab emtansine)
- Perjeta (Pertuzumab)
- Mitotic Inhibitors
- Halaven (Eribulin)
- Taxotere (Docetaxel)
- Ixempra (Ixabepilone)
- Gemzar (Gemcitabine)
- Capecitabine (Xeloda®)
- Aromatase Inhibitors
- Femara (Leterozole)
- Aromasin (Exemestane)
- Arimidex (Anastrozole)
- Ibrance (Palbociclib)
- Afinitor (Everolimus)
- Hormone Receptor
Breast Cancer Therapeutics Market by Distribution Channel (Revenue, Million, 2014 – 2025)
- Drug Store
- Specialty Pharmacy
Breast Cancer Therapeutic Market Regional Outlook (Revenue, USD Million, 2014- 2025)
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
Breast Cancer Therapeutics Market, Breast Cancer Therapeutics Market Analytics, Breast Cancer Therapeutics Market Share, Breast Cancer Therapeutics Market Research, Breast Cancer Therapeutics Market Forecast, Breast Cancer Therapeutics Market Insight, Breast Cancer Therapeutics Market Trend, Breast Cancer Therapeutics Market Value,Breast Cancer Therapeutics Market Size, Breast Cancer Therapeutics Market Analysis, Breast Cancer Therapeutics Market Survey, Breast Cancer Drugs Market, Breast Cancer Drugs Market Analytics, Breast Cancer Drugs Market Share, Breast Cancer Drugs Market Research, Breast Cancer Drugs Market Forecast, Breast Cancer Drugs Market Insight, Breast Cancer Drugs Market Trend, Breast Cancer Drugs Market Value,Breast Cancer Drugs Market Size, Breast Cancer Drugs Market Analysis, Breast Cancer Drugs Market Survey